#Innocan Pharma #Tamar Innovest #Debenture Offering

Innocan Pharma's New Debenture Offering to Tamar Innovest

Innocan Pharma Corporation, a key player in the pharmaceutical and wellness sectors, has revealed its intention to complete an additional debenture offering. This move is directed towards its largest shareholder, Tamar Innovest Ltd., with the goal of raising $200,000 in gross proceeds. This comes shortly after a previous offering, which was completed on March 11, 2026, that involved a debenture valued at $450,000.

The terms of this new debenture will mirror those of the prior offering, which includes an annual interest rate of 10% and a maturity timeframe of 12 months from the issuance date or coinciding with the completion of Innocan's public offering plans in the United States. The security for this transaction has already been established under a general security agreement made on March 7, 2025, and relevant interests are recorded according to the laws of Alberta.

Set to close around April 1, 2026, the proceeds from this debenture offering are earmarked for enhancing Innocan's working capital and supporting its corporate initiatives. Notably, Tamar Innovest, under the management of company director Ralph Bossino, currently holds a substantial 17% stake in Innocan, thereby qualifying this transaction as a